Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Sells MassArray Instrument to Roswell Park Cancer Institute

NEW YORK, May 20 (GenomeWeb News) - Sequenom has sold a MassArray genotyping instrument to the Roswell Park Cancer Institute, the San Diego-based company said today.

 

The institute, based in Buffalo, NY, will initially use the system for pharmacogenomic studies in breast cancer patients to predict response to treatment, as well as to determine who is at risk for cardiovascular disese.

 

Sequenom's MassArray system analyzes DNA by mass spectrometry.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.